How to verify a stem-cell or exosome claim before paying
Words such as registered, compliant, regenerative, or physician-developed do not establish that an exact product is FDA-approved, proven, or appropriate.
At a glance
Ask for the exact product, source, intended use, route, FDA approval status, and evidence supporting that specific intervention. FDA says the stem-cell products it has approved in the United States are blood-forming cells derived from umbilical cord blood for disorders affecting blood production, and that there are currently no FDA-approved exosome products.1 For an investigational treatment, request the FDA-issued IND number and documentation acknowledging it before paying.2
In this guide6 sections
Name the exact intervention
Regenerative medicine marketing often groups stem cells, exosomes, amniotic fluid, Wharton’s jelly, stromal vascular fraction, conditioned media, and other products together. Their sources, composition, processing, risks, and regulatory pathways differ.
Ask the seller to identify the exact product, manufacturer or processor, tissue source, whether cells come from the patient or a donor, route of administration, proposed use, and facility that will deliver it.
- Exact product and source
- Autologous or donor-derived
- Route and intended use
- Manufacturer, processor, clinician, and facility
- Lot, handling, and adverse-event process
Check FDA status with primary evidence
FDA states that the stem-cell products it has approved are blood-forming stem cells derived from umbilical cord blood for disorders affecting blood production. FDA also states that there are currently no approved exosome products.1
FDA registered, manufactured in an FDA-registered facility, or made in an FDA-inspected laboratory does not mean the treatment itself is approved. Ask for the approval information for the exact product and exact proposed use.
An investigational treatment needs documentation
A legitimate clinical trial is not the same as an expensive treatment described as experimental. FDA advises patients considering an investigational regenerative product to ask for the FDA-issued Investigational New Drug application number and the FDA communication acknowledging the IND.2
Confirm the investigator, trial record, informed-consent process, oversight, inclusion criteria, alternatives, costs, follow-up, and what happens after an adverse event. Paying does not turn marketing into research evidence.
Separate testimonials from clinical evidence
Before-and-after stories cannot show how many patients did not improve, whether another treatment caused the change, or which adverse events occurred. Evidence should match the exact product, route, condition, and patient population being marketed.
Everdawn does not currently offer stem-cell or exosome treatment. Its Stem Cells page is a restrained coming-soon category under review, not a promise of a product, procedure, self-administration method, price, eligibility standard, or launch date.
- Avoid claims spanning many unrelated diseases
- Do not accept urgency or discounts as evidence
- Ask who manages complications and long-term follow-up
- Verify the complete cost and refund terms before payment
- Discuss established alternatives with an independent clinician
Common questions
Are any stem-cell products FDA-approved?
FDA says approved stem-cell products in the United States consist of blood-forming cells derived from umbilical cord blood for disorders affecting blood production; they are not approved for unrelated uses.
Are exosome products FDA-approved?
FDA states that there are currently no FDA-approved exosome products.1
Does FDA registration mean a stem-cell treatment is approved?
No. Facility registration or inspection is not approval of a specific treatment, product, or use.
What should a clinical trial provide?
Ask for the FDA-issued IND number and acknowledgment, the registered study record, informed consent, oversight information, costs, alternatives, and an adverse-event plan.
References
- Source 1: FDA: Consumer alert on regenerative medicine products (opens in a new tab)
- Source 2: FDA: Safety alert on unapproved stem-cell and exosome products (opens in a new tab)
- Source 3: FDA: Reporting regenerative-medicine adverse events (opens in a new tab)
A number in the text links to the source for that statement.
This guide provides general educational information and is not medical advice, diagnosis, or treatment. Treatment decisions require an appropriately licensed clinician who understands your history and circumstances.
Images are illustrations, not Everdawn members or clinicians.